Hamilton Lane Advisors’s Seres Therapeutics MCRB Stock Holding History

Hamilton Lane Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-744	Closed	-$168K	–	57
2017 Q1	$168K	Hold	744	–	–	0.08%	57
2016 Q4	$147K	Hold	744	–	–	0.1%	59
2016 Q3	$183K	Sell	744 -500	-40%	-$175K	0.09%	59
2016 Q2	$757K	Buy	+1,244	New	+$730K	0.37%	41

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hamilton Lane Advisors's MCRB Position: Q2 2017 in Review

Hamilton Lane Advisors sold out of Seres Therapeutics (MCRB) in Q2 2017, closing a stake of 744 shares — an estimated $168K sold.

Hamilton Lane Advisors first reported a position in MCRB in Q2 2016 and held it in 4 quarters. The position peaked at $757K in Q2 2016. 74 funds tracked by Wall St. Rank hold MCRB as of Q2 2017.

Hamilton Lane Advisors reported no remaining Seres Therapeutics position as of Q2 2017 after selling out during the quarter.
Hamilton Lane Advisors sold 744 Seres Therapeutics shares in Q2 2017, an estimated $168K.
Hamilton Lane Advisors first reported a position in Seres Therapeutics in Q2 2016 and held it in 4 quarters.
Hamilton Lane Advisors's Seres Therapeutics position peaked at $757K in Q2 2016.
74 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2017.

Based on Hamilton Lane Advisors's 13F filing for Q2 2017, filed 26 Jul 2017.